Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome

Article Abstract:

A trial was designed to test the hypothesis that treatment of women with the polycystic ovary syndrome with extended-release metformin is more likely to result in a live birth than is treatment with clomiphene citrate and that the combination of the two therapies would result in the highest live-birth rate. It is found that clomiphene is superior to metformin in achieving live birth in infertile women with the polycystic ovary syndrome, although multiple birth is a complication.

Product development, Drug therapy, Dosage and administration, Metformin, Infertility, Stein-Leventhal syndrome, Polycystic ovary syndrome, Clomiphene, Drug overview

---

Weathering the influenza vaccine crisis

Article Abstract:

The Chiron Corporation of San Francisco, one of the two companies licensed to provide inactivated influenza vaccine in the United States withdrew their vaccine, from the market due to contamination problem in their British manufacturing facility. Efforts are under way to determine whether additional supplies of vaccine might be obtained from a variety of sources as only half the amount of vaccine expected for the 2004 vaccination campaign are available.

Product standards, safety, & recalls, Drugs, Product defects and recalls, Influenza vaccines, Biological products industry, Chiron Corp., CHIR

---

Similar abstracts:

• Abstracts: Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. Recurrent pregnancy loss and cytokines: not as simple as it seems
• Abstracts: Bone marrow, cytokines, and bone remodeling: emerging insights into the pathophysiology of osteoporosis. Bone loss and bone size after menopause
• Abstracts: Active enforcement of cigarette control laws in the prevention of cigarette sales to minors
• Abstracts: Therapeutic targeting of innate immunity with toll-like receptor agonists and antagonists. Anthrax delivers a lethal blow to host immunity
• Abstracts: How to improve the safety of patients treated in the NHS. Erythromycin. Identifying information needs of people with multiple sclerosis

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.